KalVista reports Q3 EPS (75c), consensus (98c)

Cash, cash equivalents and marketable securities were $171.7M as of January 31, 2023 vs. $166.2M as of April 30, 2022. "We have made significant advances at KalVista over this quarter, including completing a financing that funds us into 2025, well beyond our phase 3 data results, which remain on track for the second half of this year," said Andrew Crockett, Chief Executive Officer of KalVista. "We continue to publish sebetralstat data across a wide variety of outlets, including influential medical journals such as The Lancet, and make presentations at prestigious medical and patient meetings. We remain committed to addressing the unmet needs of the hereditary angioedema community by providing sebetralstat as a significant advancement in treatment for this disease."